Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 47

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 47
---

from various reporting requirements that are applicable to other public companies that are not “emerging growth companies.”
We may remain an “emerging growth company” until the earliest of (i) the last day of our fiscal year following February 7,
2027 (the fifth anniversary of the consummation of the SPAC IPO), (ii) the last day of the fiscal year in which the market value of our
shares of common stock that are held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (iii) the last day of
the fiscal year in which we have total annual gross revenue of $1.235 billion or more during such fiscal year (as indexed for inflation)
or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt in the prior three-year period. Further, there
is no guarantee that the exemptions available to us under the JOBS Act will result in significant savings. To the extent we choose not
to use exemptions from various reporting requirements under the JOBS Act, we will incur additional compliance costs, which may impact
earnings.

56

We
may issue additional shares of common stock or preferred stock under an employee incentive plan or under our existing at the market offering program, which would dilute the interest of
our stockholders.

We
may issue a substantial number of additional shares of common or preferred stock under an employee incentive plan or under our ongoing at the market offering program. The issuance of
additional shares of common or preferred stock:

    ●
    may
    significantly dilute the equity interest of investors;

    ●
    may
    subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock;

    ●
    could
    cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things,
    our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers
    and directors; and

    ●
    may
    adversely affect prevailing market prices for the common stock.

Item
1B. Unresolved Staff Comments

None.

Item
1C. Cybersecurity

We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business,
financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to